J&J wins label expansion for depression therapy Spravato

Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its depression therapy Spravato (esketamine), expanding its use as a single agent for adults with major depressive disorder (MDD).

In 2019, the FDA approved